Game On for Concussion Therapies

Most concussions—mild traumatic brain injuries (TBIs)—aren’t treated. Only a fraction of people who experience concussions seek help, and those who do usually are only prescribed rest. For about 20 percent, however, rest doesn’t alleviate the symptoms. Those symptoms may persist for months or years, making daily life difficult. As yet, there is no FDA-approved treatment for mild TBI. A few companies are addressing this increasingly-acknowledged problem by developing treatments that actually target the injury itself rather than just the resulting headaches, cognitive “fuzziness,” tiredness, or other symptoms. Oxeia Biopharmaceuticals, for example, just completed an exploratory Phase IIa trial for mild traumatic brain injury (mTBI), and Astrocyte Pharmaceuticals recently completed Phase I trials for that indication. Read more >>